Skip to content
Open access

CD28-ICOS costimulation enhances the therapeutic efficacy of L1CAM-targeted CAR-T cells against ovarian and gastric cancers

Sep 2026 · Journal for ImmunoTherapy of Cancer · Vol 14, pp. e014131 · 0 citations · 30 references
Medicine

TL;DR

The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.

Abstract

Abstract Background Ovarian and gastric cancers are associated with poor prognosis and derive limited benefit from current therapies, highlighting the need for novel immunotherapeutic approaches. The L1 cell adhesion molecule (L1CAM) is aberrantly expressed in several types of solid tumors and is associated with aggressive clinical behavior. This study aimed to develop and characterize optimized L1CAM-targeted chimeric antigen receptor-T (CAR-T) cells with improved efficacy and safety, using patient-derived preclinical models of ovarian and gastric cancer. Methods L1CAM expression was assessed in tumor tissues from patients with ovarian cancer (OC;n=227) and gastric cancer (GC;n=132), followed by an analysis of its clinical impact. A panel of L1CAM-targeted CAR constructs incorporating distinct hinge and co-stimulatory domains was systematically evaluated. Functional activity was assessed by cytotoxicity and cytokine release assays using cancer cell lines and patient-derived tumor cells. Antitumor efficacy, persistence, and safety were evaluated in xenograft and patient-derived xenograft (PDX) models, including NanoLuc-based in vivo tracking of CAR-T cell distribution. Results High L1CAM expression correlated with aggressive clinicopathological features and adverse prognosis in patients with OC. Among the constructs tested, CAR-T cells incorporating an IgD/IgG1 hybrid hinge and dual CD28-ICOS co-stimulatory domains demonstrated the most potent antigen-specific activity. These cells exhibited enhanced cytotoxicity, robust interferon-γ production, and sustained functional activity. In vivo, optimized L1CAM CAR-T cells achieved complete tumor regression in OC PDX models and significant tumor suppression in GC models, with durable tumor control and CAR-T persistence. Intraperitoneal delivery further improved therapeutic efficacy and CAR-T cell localization compared with intravenous administration. Importantly, no evidence of neurotoxicity or systemic toxicity was observed, supporting a favorable safety profile. Conclusions Optimized L1CAM-targeted CAR-T cells demonstrate potent, durable, and antigen-specific antitumor activity with a favorable safety profile in preclinical models of OC and GC. The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.

Read PDF

Similar papers

Oct 2026

CLDN18.2-targeted CAR-NK cells suppress gastric cancer growth in preclinical models.

Preclinical proof-of-concept for a rationally designed CAR4-NK therapy against CLDN18.2-positive gastric cancer, in which CD28H-2B4 co-stimulatory domains enhance the effector function of CAR4-NK cells, and show the potential of irradiated CAR4-NK cells as a safer, controllable "off-the-shelf" product candidate.

Wei Li, Ying-Jia Xu, Hui-Mei Tian et al. · 0 citations
Open access Oct 2026

EPHB4-Targeted CAR-T Cells Demonstrate Antitumor Activity in an Orthotopic Tongue PDX Model of Oral Squamous Cell Carcinoma

Oral squamous cell carcinoma (OSCC) remains associated with poor outcomes and functional impairment despite multimodal treatment, underscoring the need for effective and less invasive therapeutic strategies. Ephrin type-B receptor 4 (EPHB4) is frequently expressed on OSCC cells and represents a potential target for chi...

Masaya Kinjo, Kazunobu Ohnuki, Toshihiro Suzuki et al. · 0 citations
Open access Oct 2026

Metabolic Rewiring of GPC3-Targeted CAR T Cells Expressing IL-15 and HER2-Targeted CAR T Cells via the ADA1–CD26 Axis Promotes Tumor Infiltration and Limits Systemic Toxicities

Background: Chimeric antigen receptor (CAR) T-cell therapy for solid tumors is limited by inadequate T-cell persistence and tumor infiltration, as well as treatment-associated cytokine release syndrome (CRS). To address these challenges, we developed a metabolically rewired CAR T-cell (MRCAR) platform by co-expressing...

Yue Hu, Kevin Song, Ruo-Ning Wang et al. · 0 citations
Open access Oct 2026

CD73-targeted CAR-NK cell therapy displays potent antitumor activity and translational potential in relapsed/refractory lung adenocarcinoma

Preclinical evidence is provided that CD73-CAR-NK cells exhibit potent antitumor efficacy for R/R LUAD through their dual functions of eliminating CD73-high tumor cells and resisting adenosine-mediated immunosuppressive signaling, supporting their therapeutic potential.

Qian-Qian Liu, Qi-Fei Dong, Yi-Mei Chen et al. · 0 citations
Sep 2026

Abstract B144: MUC16-directed DR5 activation by IMV-M induces selective tumor cell apoptosis and tumor regression and enhances the activity of KRAS inhibitors in preclinical pancreatic cancer models

It is demonstrated that IMV-M exhibits potent and selective antitumor activity against MUC16-positive pancreatic cancer models through targeted DR5 activation, supporting the potential development of combination regimens with KRAS-directed therapies that have demonstrated promising clinical activity in pancreatic cance...

Hai-Yong Han, M. Zucker, Sanjana Tripuraneni et al. · 0 citations
Open access Sep 2026

The phenotypic heterogeneity of tumor-derived cells in the bloodstream of pancreatic cancer patients

These findings provide a comprehensive characterization of CTCs and CTACs in PC using a multiplex biomarker panel associated with calcium signaling and immune checkpoint pathways, highlighting the pronounced heterogeneity and potential clinical relevance of these circulating cell populations.

Chrysoula Tagari, Karolina Mangani, Michael Gogolides et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.